Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT07036601

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

Led by Tonghua Dongbao Pharmaceutical Co.,Ltd · Updated on 2025-06-25

276

Participants Needed

1

Research Sites

61 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.

CONDITIONS

Official Title

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients 18 to 75 years of age, inclusive
  • BMI 63; 28 kg/m�B2 or BMI between 24 64 BMI < 28 kg/m�B2 with at least 1 weight-related comorbidity at screening: prediabetes, hypertension, metabolic-associated fatty liver disease, dyslipidemia, weight-bearing joint pain, or obstructive sleep apnea syndrome
  • Diet and exercise control for at least 3 months before screening visit, with less than 5% self-reported weight change within the last 3 months
Not Eligible

You will not qualify if you...

  • History of diabetes
  • History of obesity caused by endocrine diseases, monogenic mutations, or drug-induced causes such as hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism
  • Weight gain resulting from increased non-fat mass (e.g., edema)
  • Uncontrolled hypertension at screening: systolic blood pressure 63;160 mmHg and/or diastolic blood pressure 63;100 mmHg
  • ECG findings at screening including heart rate <50 bpm or >100 bpm; QTcF prolongation (>450 ms for males, >470 ms for females); PR interval >200 ms; long QT syndrome; second- or third-degree atrioventricular block; left bundle branch block; complete right bundle branch block; Wolff-Parkinson-White syndrome
  • Any other condition deemed unsuitable for participation by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second Xiangya Hospital of Central South University

Changsha, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here